EPIDEMIOLOGY OF MYELODYSPLASTIC SYNDROMES IN MOSCOW ACCORDING TO REGIONAL REGISTER
Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for leu- kemic transformation. The data on the epidemiology of MDS in Russia are absent. The aim of the study was to evaluate the incidence and methods of MDS diagnosis and efficacy of treatment of adults in Moscow Health Care system. The obtained results show that for the first time MDS was diagnosed in 201 adult patients (male - 92, female - 109), being permanent residents of Moscow. Median age at diagnosis was 71,5 years (range, 23,9-93,7). The incidence rate of MDS was 2,0 cases per 100.000 persons per year. 4-year overall survival (OS) for all patients was 34,8 ± 13,4% (median 24,3 months).Thus, the incidence of MDS in Moscow, Russia is 1,5-2 times lower than in Europe and the United States. Current standards donot provide molecular and cytogenetic assays, what is the factors limiting the diagnostic potential.
About the Authors
S. V. Semochkin
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Russian Federation
Russian Federation
G. A. Dudina
ГБУЗ «Московский клинический научно-практический центр ДЗМ»
Russian Federation
Russian Federation
T. N. Tolstykh
ГБУЗ «Городская клиническая больница №52 ДЗМ»
Russian Federation
Russian Federation
References
1. Bennett, J.M. Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms / J.M. Bennett // Clin Lymphoma Myeloma Leuk. - 2016. - Vol. 16, № 11. - P. 607-609
2. Myelodysplastic syndromes in the United States: an update for clinicians / J.D. Troy [et al.] // Ann Med. - 2014. - Vol. 46, № 5. - P. 283-289
3. Causes of death in 2877 patients with myelodysplastic syndromes / K. Nachtkamp [et al.] // Ann Hematol. - 2016. - Vol. 95, № 6.):937-44
4. Gangat, N. Myelodysplastic syndromes: Contemporary review and how we treat / N. Gangat, M.M. Patnaik, A. Tefferi // Am J Hematol. - 2016. - Vol. 91, № 1. - P. 76-89
5. Национальные клинические рекомендации по диагностике и лечению миелодиспластических синдромов у взрослых / В.Г. Савченко [и др.] // Гематология и трансфузиология. - 2016. - T. 61, № 1. - С. 1-32
6. International scoring system for evaluating prognosis in myelodysplastic syndromes / P. Greenberg [et al.] // Blood. - 1997. - Vol. 89, № 6. - P. 2079-2088
7. Revised international prognostic scoring system for myelodysplastic syndromes / P.L. Greenberg [et al.] // Blood. - 2012. - Vol. 120, №12. - P. 2454-2465
8. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes // J.W. Vardiman [et al.] // Blood. - 2009. - Vol. 114, № 5. - P. 937-951
9. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia // B.D. Cheson [et al.] // Blood. - 2006. - Vol. 108, № 2. - P. 419-425
10. Грицаев, С.В. Мелодиспластический синдром с del(5q) и леналидомид / С.В.Грицаев, И.С. Мартынкевич, Е.В. Петрова // Гематология и трансфузиология. - 2013. - Т. 58, № 2. - С. 3-10
11. Клиническая эффективность Дакогена при миелодиспластическом синдроме / А.К. Голенков [и др.] // Онкогематология. - 2008. - № 4. - С. 36-38. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study // P. Fenaux [et al.] // Lancet Oncol. - 2009. - Vol. 10, №3. - P. 223-232
Review
For citations:
Semochkin S.V., Dudina G.A., Tolstykh T.N. EPIDEMIOLOGY OF MYELODYSPLASTIC SYNDROMES IN MOSCOW ACCORDING TO REGIONAL REGISTER. Bashkortostan Medical Journal. 2017;12(2):153-156. (In Russ.)
Views:
98
Email this article 
